Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H5O7.3K.H2O |
| Molecular Weight | 324.4099 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
InChI
InChIKey=PJAHUDTUZRZBKM-UHFFFAOYSA-K
InChI=1S/C6H8O7.3K.H2O/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;1H2/q;3*+1;/p-3
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.adm.com/en-US/worldwide/australia/Documents/Potassium%20Citrate%20AU.pdf | https://noshly.com/additive/e332/acidity-regulator-plus/332/#.WUp-1uvyjIU
Curator's Comment: Description was created based on several sources, including
http://www.adm.com/en-US/worldwide/australia/Documents/Potassium%20Citrate%20AU.pdf | https://noshly.com/additive/e332/acidity-regulator-plus/332/#.WUp-1uvyjIU
Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. WhenPotassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. Potassium citrate is used as a food additive (E 332) to regulate acidity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0010447 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | UROCIT-K Approved UseUrocit®-K is a citrate salt of potassium indicated for the management of:
• Renal tubular acidosis (RTA) with calcium stones
• Hypocitraturic calcium oxalate nephrolithiasis of any etiology
• Uric acid lithiasis with or without calcium stones Launch Date1985 |
|||
| Primary | UROCIT-K Approved UseUrocit®-K is a citrate salt of potassium indicated for the management of:
• Renal tubular acidosis (RTA) with calcium stones
• Hypocitraturic calcium oxalate nephrolithiasis of any etiology
• Uric acid lithiasis with or without calcium stones Launch Date1985 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
540 mg 1 times / day multiple, oral Recommended Dose: 540 mg, 1 times / day Route: oral Route: multiple Dose: 540 mg, 1 times / day Co-administed with:: Thiamin oral 1.1 mg Sources: Page: p.2326Arginine oral 1240 mg caffeine oral 52 mg |
healthy, 24-59 n = 16 Health Status: healthy Age Group: 24-59 Sex: M+F Population Size: 16 Sources: Page: p.2326 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparative efficacy of "specific" potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity. | 1985 Oct |
|
| Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate. | 1993 |
Sample Use Guides
Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary
pH to a level of 6.0 to 7.0.
• Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack
• Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times per day with meals or within 30 minutes after meals or bedtime snack
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
JECFA EVALUATION |
INS-332(II)
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/17/1888
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
FDA ORPHAN DRUG |
2784
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
DSLD |
2904 (Number of products:56)
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-332(II)
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
NDF-RT |
N0000175896
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
CFR |
21 CFR 184.1625
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
FDA ORPHAN DRUG |
9785
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
NCI_THESAURUS |
C29730
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
WHO-ATC |
A12BA02
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
WHO-VATC |
QA12BA02
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
FDA ORPHAN DRUG |
9685
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
||
|
FDA ORPHAN DRUG |
913522
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
EE90ONI6FF
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
64746
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
2735208
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
EE90ONI6FF
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
221149
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
64733
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200458
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
6100-05-6
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
4519
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
POTASSIUM CITRATE
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | Description: Transparent crystals or a white, granular powder; odourless. Solubility: Freely soluble in water; practically insoluble in ethanol (~750 g/l) TS. Category: Systemic alkalinizing substance; component of oral rehydration salt mixtures. Storage: Potassium citrate should be kept in a tightly closed container. Additional information: Potassium citrate is deliquescent when exposed to moist air. Definition: Potassium citrate contains not less than 99.0% and not more than 101.0% of C6H5K3O7, calculated with reference tothe anhydrous substance. | ||
|
C29372
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
POTASSIUM CITRATE
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
DB09125
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
SUB14973MIG
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
D019357
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
760107
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
DTXSID8042501
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
SUB75022
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
m9014
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
1548225
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
PRIMARY | |||
|
54993
Created by
admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
|
ALTERNATIVE |
ACTIVE MOIETY
SUBSTANCE RECORD
